Reckitt Unveils Its Largest Over-the-Counter Manufacturing Plant in the U.S.
Reckitt Benckiser Group Plc, commonly known as Reckitt, has made a significant investment in the healthcare sector by establishing its largest over-the-counter (OTC) manufacturing facility in Wilson, North Carolina. This state-of-the-art factory marks a major milestone for the company, as it aims to enhance production capabilities for its leading product, Mucinex®, to meet the growing consumer demand for cold and flu symptom relief in the United States.
Located near the Research Triangle, a renowned life sciences hub, the new facility represents an investment of approximately £155 million, or $200 million. Company officials are optimistic that this facility will strengthen the supply chain in their largest market, ensuring that they can respond more effectively to fluctuating demand during cold and flu seasons. Reckitt's Chief Supply Officer, Harald Emberger, highlighted the importance of this expansion: "Mucinex is our #1 over-the-counter product in the U.S. and the #1 global cough and decongestant medicine. With the rise in demand for cold and flu relief, we are taking action to expand access to our products and build a more resilient supply chain."
The Wilson facility will expand Reckitt's production capacity significantly, adding nearly 300 jobs to the local economy. Additionally, the factory will be capable of producing an extensive range of products, not only Mucinex but also future formulations such as Move Free® and Biofreeze®. This expansion is crucial as the demand for cold and flu medications has risen beyond pre-pandemic averages, influenced by fluctuating illness patterns observed in recent years.
Historically, respiratory virus burdens have proven unpredictable, and this tends to become even more pronounced post-pandemic. According to the Centers for Disease Control and Prevention (CDC), adults in the U.S. typically experience two to three colds annually, while children may experience even higher rates of illness. The CDC reported that the 2023-2024 flu season alone was associated with approximately 40 million illnesses and 470,000 hospitalizations. Moreover, respiratory illnesses, including off-season COVID-19 infections, add to the complexities of illness trends.
Given these dynamics, Reckitt is preparing to meet increasing consumer needs with agility, including the introduction of innovative products like Mucinex Mighty Chews and Mucinex 2-in-1 Nasal Spray. The expansive 310,000 square foot facility is poised to enhance efficiency and quality, better serving consumers during peak seasons and unexpected surges alike.
Reckitt's commitment to health and wellness stands as a testament to its broader mission to protect, heal, and nurture through world-class hygiene, health, and nutrition products. The company is recognized globally for its various consumer brands, including Air Wick, Calgon, Clearasil, Dettol, and more. By investing in local manufacturing capabilities, Reckitt not only aims to improve product access but also to contribute positively to job creation and the local economy.
As this facility comes online, it strengthens Reckitt's resolve to deliver quality healthcare products while addressing the ever-evolving needs of its consumers. For more than 20 years, Mucinex has been a trusted ally for those seeking relief from mucus and congestion. Now, with the addition of the Wilson facility, Reckitt is poised to ensure that they can continue to provide consumers with the vital relief they seek, whenever they need it.
Located near the Research Triangle, a renowned life sciences hub, the new facility represents an investment of approximately £155 million, or $200 million. Company officials are optimistic that this facility will strengthen the supply chain in their largest market, ensuring that they can respond more effectively to fluctuating demand during cold and flu seasons. Reckitt's Chief Supply Officer, Harald Emberger, highlighted the importance of this expansion: "Mucinex is our #1 over-the-counter product in the U.S. and the #1 global cough and decongestant medicine. With the rise in demand for cold and flu relief, we are taking action to expand access to our products and build a more resilient supply chain."
The Wilson facility will expand Reckitt's production capacity significantly, adding nearly 300 jobs to the local economy. Additionally, the factory will be capable of producing an extensive range of products, not only Mucinex but also future formulations such as Move Free® and Biofreeze®. This expansion is crucial as the demand for cold and flu medications has risen beyond pre-pandemic averages, influenced by fluctuating illness patterns observed in recent years.
Historically, respiratory virus burdens have proven unpredictable, and this tends to become even more pronounced post-pandemic. According to the Centers for Disease Control and Prevention (CDC), adults in the U.S. typically experience two to three colds annually, while children may experience even higher rates of illness. The CDC reported that the 2023-2024 flu season alone was associated with approximately 40 million illnesses and 470,000 hospitalizations. Moreover, respiratory illnesses, including off-season COVID-19 infections, add to the complexities of illness trends.
Given these dynamics, Reckitt is preparing to meet increasing consumer needs with agility, including the introduction of innovative products like Mucinex Mighty Chews and Mucinex 2-in-1 Nasal Spray. The expansive 310,000 square foot facility is poised to enhance efficiency and quality, better serving consumers during peak seasons and unexpected surges alike.
Reckitt's commitment to health and wellness stands as a testament to its broader mission to protect, heal, and nurture through world-class hygiene, health, and nutrition products. The company is recognized globally for its various consumer brands, including Air Wick, Calgon, Clearasil, Dettol, and more. By investing in local manufacturing capabilities, Reckitt not only aims to improve product access but also to contribute positively to job creation and the local economy.
As this facility comes online, it strengthens Reckitt's resolve to deliver quality healthcare products while addressing the ever-evolving needs of its consumers. For more than 20 years, Mucinex has been a trusted ally for those seeking relief from mucus and congestion. Now, with the addition of the Wilson facility, Reckitt is poised to ensure that they can continue to provide consumers with the vital relief they seek, whenever they need it.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.